RECRUITINGOBSERVATIONAL
A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea
Post-Marketing Surveillance (PMS) Study on Zeposia® (Ozanimod) Use Among Moderate to Severe Active Ulcerative Colitis Patients in Korea
About This Trial
The purpose of this observational study is to assess the real-world safety of ozanimod in Korean participants with moderate to severe active ulcerative colitis.
Who May Be Eligible (Plain English)
Who May Qualify:
- Adult participants 19 years of age or older
- Participants who will receive ozanimod according to the approved label after enrollment
- Participants who sign the willing to sign a consent form form voluntarily
Who Should NOT Join This Trial:
- Participants who are prescribed ozanimod for therapeutic indications not approved in Korea
- Participants for whom ozanimod is contraindicated as clarified in Korean prescribing information approved by Ministry of Food and Drug Safety
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Adult participants 19 years of age or older
* Participants who will receive ozanimod according to the approved label after enrollment
* Participants who sign the informed consent form voluntarily
Exclusion Criteria:
* Participants who are prescribed ozanimod for therapeutic indications not approved in Korea
* Participants for whom ozanimod is contraindicated as clarified in Korean prescribing information approved by Ministry of Food and Drug Safety
Treatments Being Tested
DRUG
Ozanimod
According to local product label
Locations (1)
Bristol-Myers Squibb YH
Seoul, South Korea